+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Psychedelic Drug Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F- Product Image
Psychedelic Drug Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F- Product Image
New

Psychedelic Drug Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • PDF Icon

    Report

  • 186 Pages
  • March 2025
  • Region: Global
  • TechSci Research
  • ID: 5908394
Free Webex Call
10% Free customization
Description Jump to:
Free Webex Call

Speak directly to the analyst to clarify any post sales queries you may have.

 10% Free customization

This report comes with 10% free customization, enabling you to add data that meets your specific business needs.
The Psychedelic Drug Market was valued at USD 4.55 Billion in 2024, and is expected to reach USD 8.32 Billion by 2030, rising at a CAGR of 10.55%. The global psychedelic drug market is witnessing a renewed surge in interest and expansion, fueled by significant advancements in clinical research, evolving regulatory frameworks, and shifting societal perceptions. The rising prevalence of mental health disorders - particularly depression, anxiety, and post-traumatic stress disorder (PTSD) - has created an urgent demand for innovative and effective treatment solutions. Psychedelic-based therapeutics are gaining traction as a disruptive alternative to conventional antidepressants, demonstrating both rapid onset and sustained efficacy in clinical trials.

Market growth is being further catalyzed by increasing mental health awareness, progressive policy reforms, and a growing body of scientific evidence supporting the medical utility of psychedelics. Strategic partnerships between pharmaceutical companies, biotech firms, and research institutions are accelerating drug development pipelines, positioning psychedelic compounds for potential mainstream integration within psychiatric care. As regulatory approvals expand and investment in research and development intensifies, the psychedelic drug market is poised for substantial long-term growth.

Key Market Drivers

Rising Prevalence of Mental Health Disorders

The increasing global prevalence of mental health disorders is one of the most significant catalysts driving the growth of the psychedelic drugs market. As traditional treatment approaches struggle to meet the rising demand for effective solutions, psychedelic-assisted therapies are emerging as a disruptive innovation in psychiatric care. The burden of mental health disorders has reached unprecedented levels, with conditions such as depression, anxiety, and post-traumatic stress disorder (PTSD) affecting millions worldwide. According to data from the World Health Organization (WHO), depression affects more than 284 million individuals worldwide, making it one of the most widespread mental health conditions.

Similarly, over 264 million people are impacted by anxiety disorders, highlighting the growing demand for effective mental health interventions. Despite these alarming statistics, conventional treatments - including selective serotonin reuptake inhibitors (SSRIs) and cognitive-behavioral therapy (CBT) - often produce suboptimal results, with many patients experiencing delayed symptom relief, treatment resistance, or severe side effects. This growing treatment gap has created a strong demand for innovative therapies, positioning psychedelics as a viable alternative.

Key Market Challenges

Regulatory Hurdles

Perhaps the most significant challenge facing the psychedelic drug market is the complex and evolving regulatory landscape. Many psychedelics are classified as controlled substances due to their historical association with recreational use and concerns about safety and abuse potential. Navigating these regulations can be a lengthy and expensive process, often requiring years of clinical trials and regulatory approvals.

Key Market Players

  • Jazz Pharmaceuticals PLC
  • NeonMind Biosciences Inc.
  • Cybin Inc.
  • Pfizer Inc
  • Numinus Wellness Inc
  • Mind Medicine Inc
  • PharmaTher Holdings Ltd
  • NRX Pharmaceuticals Inc
  • Seelos Therapeutics Inc
  • Revive Therapeutics Inc

Report Scope:

In this report, the Global Psychedelic Drug Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Psychedelic Drug Market, By Drug Type:

  • Lysergic Acid Diethylamide
  • Gamma Hydroxybutyric Acid
  • Ketamine
  • Psilocybin
  • Others

Psychedelic Drug Market, By Application:

  • Treatment-Resistant Depression
  • Opiate Addiction
  • Post-Traumatic Stress Disorder
  • Narcolepsy
  • Panic Disorders
  • Others

Psychedelic Drug Market, By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Psychedelic Drug Market, By Region:

  • North America
  • United States
  • Canada
  • Mexico
  • Europe
  • Germany
  • United Kingdom
  • France
  • Italy
  • Spain
  • Asia-Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Psychedelic Drug Market.

Available Customizations:

With the given market data, the publisher offers customizations according to a company's specific needs. The following customization options are available for the report.

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.

Table of Contents

1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Psychedelic Drug Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Drug Type (Lysergic Acid Diethylamide, Gamma Hydroxybutyric Acid, Ketamine, Psilocybin, Others)
5.2.2. By Application (Treatment-Resistant Depression, Opiate Addiction, Post-Traumatic Stress Disorder, Narcolepsy, Panic Disorders, Others)
5.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
5.2.4. By Region
5.2.5. By Company (2024)
5.3. Product Market Map
5.3.1. By Drug Type
5.3.2. By Application
5.3.3. By Distribution Channel
5.3.4. By Region
6. North America Psychedelic Drug Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Drug Type (Lysergic Acid Diethylamide, Gamma Hydroxybutyric Acid, Ketamine, Psilocybin, Others)
6.2.2. By Application (Treatment-Resistant Depression, Opiate Addiction, Post-Traumatic Stress Disorder, Narcolepsy, Panic Disorders, Others)
6.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
6.2.4. By Country
6.3. North America: Country Analysis
6.3.1. United States Psychedelic Drug Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Drug Type
6.3.1.2.2. By Application
6.3.1.2.3. By Distribution Channel
6.3.2. Canada Psychedelic Drug Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Drug Type
6.3.2.2.2. By Application
6.3.2.2.3. By Distribution Channel
6.3.3. Mexico Psychedelic Drug Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Drug Type
6.3.3.2.2. By Application
6.3.3.2.3. By Distribution Channel
7. Europe Psychedelic Drug Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Drug Type (Lysergic Acid Diethylamide, Gamma Hydroxybutyric Acid, Ketamine, Psilocybin, Others)
7.2.2. By Application (Treatment-Resistant Depression, Opiate Addiction, Post-Traumatic Stress Disorder, Narcolepsy, Panic Disorders, Others)
7.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
7.2.4. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Psychedelic Drug Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Drug Type
7.3.1.2.2. By Application
7.3.1.2.3. By Distribution Channel
7.3.2. United Kingdom Psychedelic Drug Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Drug Type
7.3.2.2.2. By Application
7.3.2.2.3. By Distribution Channel
7.3.3. France Psychedelic Drug Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Drug Type
7.3.3.2.2. By Application
7.3.3.2.3. By Distribution Channel
7.3.4. Italy Psychedelic Drug Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Drug Type
7.3.4.2.2. By Application
7.3.4.2.3. By Distribution Channel
7.3.5. Spain Psychedelic Drug Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Drug Type
7.3.5.2.2. By Application
7.3.5.2.3. By Distribution Channel
8. Asia-Pacific Psychedelic Drug Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Drug Type (Lysergic Acid Diethylamide, Gamma Hydroxybutyric Acid, Ketamine, Psilocybin, Others)
8.2.2. By Application (Treatment-Resistant Depression, Opiate Addiction, Post-Traumatic Stress Disorder, Narcolepsy, Panic Disorders, Others)
8.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
8.2.4. By Country
8.3. Asia-Pacific: Country Analysis
8.3.1. China Psychedelic Drug Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Drug Type
8.3.1.2.2. By Application
8.3.1.2.3. By Distribution Channel
8.3.2. Japan Psychedelic Drug Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Drug Type
8.3.2.2.2. By Application
8.3.2.2.3. By Distribution Channel
8.3.3. India Psychedelic Drug Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Drug Type
8.3.3.2.2. By Application
8.3.3.2.3. By Distribution Channel
8.3.4. Australia Psychedelic Drug Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Drug Type
8.3.4.2.2. By Application
8.3.4.2.3. By Distribution Channel
8.3.5. South Korea Psychedelic Drug Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Drug Type
8.3.5.2.2. By Application
8.3.5.2.3. By Distribution Channel
9. South America Psychedelic Drug Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Drug Type (Lysergic Acid Diethylamide, Gamma Hydroxybutyric Acid, Ketamine, Psilocybin, Others)
9.2.2. By Application (Treatment-Resistant Depression, Opiate Addiction, Post-Traumatic Stress Disorder, Narcolepsy, Panic Disorders, Others)
9.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
9.2.4. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Psychedelic Drug Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Drug Type
9.3.1.2.2. By Application
9.3.1.2.3. By Distribution Channel
9.3.2. Argentina Psychedelic Drug Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Drug Type
9.3.2.2.2. By Application
9.3.2.2.3. By Distribution Channel
9.3.3. Colombia Psychedelic Drug Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Drug Type
9.3.3.2.2. By Application
9.3.3.2.3. By Distribution Channel
10. Middle East and Africa Psychedelic Drug Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Drug Type (Lysergic Acid Diethylamide, Gamma Hydroxybutyric Acid, Ketamine, Psilocybin, Others)
10.2.2. By Application (Treatment-Resistant Depression, Opiate Addiction, Post-Traumatic Stress Disorder, Narcolepsy, Panic Disorders, Others)
10.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
10.2.4. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa Psychedelic Drug Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Drug Type
10.3.1.2.2. By Application
10.3.1.2.3. By Distribution Channel
10.3.2. Saudi Arabia Psychedelic Drug Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Drug Type
10.3.2.2.2. By Application
10.3.2.2.3. By Distribution Channel
10.3.3. UAE Psychedelic Drug Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Drug Type
10.3.3.2.2. By Application
10.3.3.2.3. By Distribution Channel
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Recent Development
12.2. Mergers & Acquisitions
12.3. Product Launches
13. Porter’s Five Forces Analysis
13.1. Competition in the Industry
13.2. Potential of New Entrants
13.3. Power of Suppliers
13.4. Power of Customers
13.5. Threat of Substitute Products
14. Competitive Landscape
14.1. Jazz Pharmaceuticals PLC
14.1.1. Business Overview
14.1.2. Product & Service Offerings
14.1.3. Recent Developments
14.1.4. Financials (If Listed)
14.1.5. Key Personnel
14.1.6. SWOT Analysis
14.2. NeonMind Biosciences Inc.
14.3. Cybin Inc.
14.4. Pfizer Inc
14.5. Numinus Wellness Inc
14.6. Mind Medicine Inc
14.7. PharmaTher Holdings Ltd
14.8. NRX Pharmaceuticals Inc
14.9. Seelos Therapeutics Inc
14.10. Revive Therapeutics Inc
15. Strategic Recommendations16. About the Publisher & Disclaimer

Companies Mentioned

  • Jazz Pharmaceuticals PLC
  • NeonMind Biosciences Inc.
  • Cybin Inc.
  • Pfizer Inc
  • Numinus Wellness Inc
  • Mind Medicine Inc
  • PharmaTher Holdings Ltd
  • NRX Pharmaceuticals Inc
  • Seelos Therapeutics Inc
  • Revive Therapeutics Inc

Table Information

Report AttributeDetails
No. of Pages186
PublishedMarch 2025
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 4.55 Billion
Forecasted Market Value ( USD ) by 2030 $ 8.32 Billion
Compound Annual Growth Rate10.5%
Regions CoveredGlobal
No. of Companies Mentioned10

Related Topics

Related Reports

Psychedelic Drugs Market Report 2025 - Product Image

Psychedelic Drugs Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Psychedelic Drugs Market 2024-2028 - Product Image

Psychedelic Drugs Market 2024-2028

  • Report
  • 189 Pages
  • Global
From
Clinical Trials: Psychedelic Therapeutics - Product Image

Clinical Trials: Psychedelic Therapeutics

  • Report
  • 32 Pages
  • Global
From
Psychedelics in Psychiatry. International Review of Neurobiology Volume 181 - Product Image

Psychedelics in Psychiatry. International Review of Neurobiology Volume 181

  • Book
  • Global
Therapies for Treatment-Resistant Depression. Neuropharmacology and Neurostimulation - Product Image

Therapies for Treatment-Resistant Depression. Neuropharmacology and Neurostimulation

  • Book
Copyright © 2002-2025 Research and Markets. All Rights Reserved.